Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 5/20 | 0.46 |
| ▸ | CNR2 | P34972 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5807418 | 0.97 | CNR1 (0.49) | CNR1CNR2ALDH1A1MAPTHPGD | |
| SCHEMBL25303134 | 0.97 | EPHX2 (0.47) | SOAT1CNR2MEN1KMT2AEPHX2 | |
| SCHEMBL1736038 | 0.97 | EPHX2 (0.47) | SOAT1CNR2MEN1KMT2AEPHX2 | |
| SCHEMBL3285881 | 0.90 | DPP7 (0.44) | MAPT | |
| SCHEMBL3283700 | 0.90 | DPP7 (0.44) | MAPT | |
| SCHEMBL11052070 | 0.90 | DPP7 (0.44) | MAPT | |
| SCHEMBL539143 | 0.90 | DPP7 (0.44) | MAPT | |
| SCHEMBL5183216 | 0.90 | DPP7 (0.44) | MAPT | |
| SCHEMBL25303264 | 0.90 | DPP7 (0.44) | MAPT | |
| SCHEMBL1690132 | 0.90 | DPP7 (0.44) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109890361-B | Compositions containing linoleic acid | 太阳星光齿磨公司 | 2023-02-24 | — | — | CN | disclosed |
| EP-2668939-B1 | COMPOSITION CONTAINING POLYUNSATURATED FATTY ACID | SUNSTAR INC (JP) | 2020-06-17 | — | — | EP | disclosed |
| US-10472379-B2 | Ruthenium-sphingomyelin complexes and methods for their use in the treatment of tumors | GARNETT MCKEEN LAB, INC. | 2019-11-12 | — | — | US | disclosed |
| EP-3533437-A1 | COMPOSITION CONTAINING LINOLEIC ACID | Sunstar Inc. (JP) | 2019-09-04 | — | — | EP | disclosed |
| US-20190247290-A1 | COMPOSITION CONTAINING LINOLEIC ACID | SUNSTAR INC. (JP) | 2019-08-15 | — | — | US | disclosed |
| US-20180051045-A1 | RUTHENIUM-SPHINGOMYELIN COMPLEXES AND METHODS FOR THEIR USE IN THE TREATMENT OF TUMORS | GARNETT MCKEEN LAB, INC. | 2018-02-22 | — | — | US | disclosed |
| WO-2017200792-A1 | RUTHENIUM-SPHINGOMYELIN COMPLEXES AND METHODS FOR THEIR USE IN THE TREATMENT OF TUMORS | GARNETT MCKEEN LAB, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| US-9605012-B2 | Palladium-ruthenium-zinc-organo complexes and methods for their use in the treatment of inflammatory diseases | GARNETT MCKEEN LABORATORY, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| CN-103338746-B | Compositions containing polyunsaturated fatty acid | SUNSTAR INC. (JP) | 2015-12-23 | — | — | CN | disclosed |
| US-8940312-B2 | Composition containing polyunsaturated fatty acid | SUNSTAR INC. (JP) | 2015-01-27 | — | — | US | disclosed |
| WO-2014164902-A1 | PALLADIUM-RUTHENIUM-ZINC-ORGANO COMPLEXES AND METHODS FOR THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | GARNETT MCKEEN LABORATORY, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| EP-2668939-A1 | COMPOSITION CONTAINING POLYUNSATURATED FATTY ACID | SUNSTAR INC. (JP) | 2013-12-04 | — | — | EP | disclosed |
| US-20130287827-A1 | COMPOSITION CONTAINING POLYUNSATURATED FATTY ACID | SUNSTAR INC. (JP) | 2013-10-31 | — | — | US | disclosed |
| CN-103338746-A | Composition containing polyunsaturated fatty acid | SUNSTAR INC | 2013-10-02 | — | — | CN | disclosed |
| WO-2010046542-A1 | METHOD FOR PREPARING MODIFIED FIBER PRODUCTS | OY KESKUSLABORATORIO - CENTRALLABORATORIUM AB (FI) | 2010-04-29 | — | — | WO | disclosed |
| US-6669932-B2 | Mixture of unsaturated fatty acid, phosphatides, antioxidizer, protein and mucopolysaccharides | SUNSTAR INC. (JP) | 2003-12-30 | — | — | US | disclosed |
| CN-1125634-C | Skin-lightening cosmetic | SUNSTAR INC (JP) | 2003-10-29 | — | — | CN | disclosed |
| US-20030103916-A1 | SKIN-WHITENING COSMETIC | SUNSTAR INC. (JP) | 2003-06-05 | — | — | US | disclosed |
| EP-0992236-B1 | SKIN-LIGHTENING COSMETIC | SUNSTAR INC (JP) | 2003-04-02 | — | — | EP | disclosed |
| EP-0992236-A1 | SKIN-LIGHTENING COSMETIC | Sunstar Inc. (JP) | 2000-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10472379-B2 | Ruthenium-sphingomyelin complexes and methods for their use in the treatment of tumors | SGMS2, SGMS1, SMPD4 | KDM4E 3334/4885SOAT1 53/4885CNR1 2952/4885 |
| US-20180051045-A1 | RUTHENIUM-SPHINGOMYELIN COMPLEXES AND METHODS FOR THEIR USE IN THE TREATMENT OF TUMORS | SGMS2, SGMS1, SMPD4 | KDM4E 3334/4885SOAT1 53/4885CNR1 2952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.